USGIF Honors Vice Admiral Robert Sharp, USN (Ret.), with 2025 Lundahl-Finnie Lifetime Achievement Award
The United States Geospatial Intelligence Foundation (USGIF) is proud to announce Vice Admiral Robert 'Bob' Sharp, USN (Ret.), as the recipient of the 2025 Arthur C. Lundahl-Thomas C. Finnie Lifetime Achievement Award. This prestigious award recognizes individuals who have made distinguished, long-standing contributions to the geospatial intelligence (GEOINT) tradecraft and community. VADM Sharp is being honored for more than three decades of service and leadership in national security and intelligence, culminating in his tenure as the Director of the National Geospatial-Intelligence Agency (NGA) from 2019 to 2022.
As Director of NGA, VADM Sharp led a global workforce of more than 14,000 professionals across 120+ locations, delivering trusted geospatial intelligence to decision-makers, warfighters, first responders, and allies. His leadership was instrumental in modernizing NGA operations during the COVID-19 pandemic, emphasizing agility, resilience, and a people-centered approach.
A Naval Intelligence Officer for more than 34 years, VADM Sharp played a pivotal role within the Navy's Information Warfare Community. Known for fostering high-performing teams and strategic transformation, his career reflects a deep commitment to service, collaboration, and excellence.
VADM Sharp earned a Bachelor of Arts from the University of the Pacific and a Master of Science in National Resource Strategy from the Industrial College of the Armed Forces. In his current role as CEO of B Sharp – Global Solutions, he advises organizations dedicated to making a positive global impact.
The award will be formally presented at the annual GEOGala, taking place on Friday, December 5, 2025, at the Ritz-Carlton in Tysons, VA.
About USGIF:
The United States Geospatial Intelligence Foundation is a non-profit educational foundation dedicated to promoting the geospatial intelligence tradecraft and building a stronger GEOINT community through education, professional development, and innovation.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250630231803/en/
CONTACT: Sabrina Castellanos, Senior Communications Manager
United States Geospatial Intelligence Foundation (USGIF)
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA VIRGINIA
INDUSTRY KEYWORD: PUBLIC POLICY/GOVERNMENT DEFENSE OTHER DEFENSE OTHER EDUCATION HOMELAND SECURITY EDUCATION AEROSPACE MANUFACTURING
SOURCE: The United States Geospatial Intelligence Foundation
Copyright Business Wire 2025.
PUB: 06/30/2025 11:12 AM/DISC: 06/30/2025 11:12 AM
http://www.businesswire.com/news/home/20250630231803/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
22 minutes ago
- Business Wire
Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) resulting from allegations that Telix may have issued materially misleading business information to the investing public. So What: If you purchased Telix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@ for information on the class action. What is this about: On July 22, 2025, Telix disclosed receipt of a subpoena from the U.S. Securities and Exchange Commission, which was 'seeking various documents and information primarily relating to the Company's disclosures regarding the development of the Company's prostate cancer therapeutic candidates.' On this news, Telix's American Depositary Receipt ('ADR') price fell $1.70 per ADR, or 10.44%, to close at $14.58 per ADR on July 23, 2025. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Attorney Advertising. Prior results do not guarantee a similar outcome.
Business Wire
an hour ago
- Business Wire
AAHI Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines
SEATTLE--(BUSINESS WIRE)--Access to Advanced Health Institute (AAHI), a global leader in translating high-impact science into scalable, field-ready vaccine solutions, today announced an exciting new partnership with Quratis, a premier biotechnology company and advanced Contract Development and Manufacturing Organization (CDMO). This collaboration marks a pivotal step forward in breaking through barriers in global health equity around the world. Under this strategic alliance, Quratis has been selected as AAHI's preferred manufacturer for high-quality pre-clinical and clinical vaccine supplies, with the capacity to expand into commercial-scale production for global markets. This collaboration will accelerate the development of AAHI's innovative vaccine candidates targeting deadly diseases such as tuberculosis, and of vaccines that rely on AAHI's vaccine adjuvants to provide protection against malaria, HIV, and other global health threats. Quratis brings a world-class GMP-certified bioplant and cutting-edge CDMO expertise in biopharmaceutical raw material development, process optimization, and finished pharmaceutical manufacturing. By designating Quratis as preferred partner, AAHI strengthens both its scientific capabilities and access to scalable, cost-effective production of its groundbreaking vaccine formulations—including dry vaccines that eliminate cold chain dependencies and needle-free delivery systems for superior respiratory protection. The partnership ensures a seamless supply chain platform, enabling swift clinical development and broader deployment to the world's most vulnerable populations. "Partnering with Quratis is a very important step in AAHI's strategy to advance practical, life-saving vaccines, that can be deployed at scale where they're needed most,' said Keeley Foley, CEO of AAHI. 'Quartis' innovative cutting edge, safe, world-class CDMO capabilities makes it possible for AAHI to deliver on our mission – and helps ensure our efforts to combat infectious diseases and foster health autonomy worldwide. Together, we're not just manufacturing vaccines—we're delivering an important mission to revolutionize global health." Quratis, renowned for its global innovation in healthcare, brings unparalleled expertise in vaccine development and manufacturing to the table. With a track record of success in TB and COVID-19 vaccines like QTP101 and QTP104, Quratis' advanced processes will enhance AAHI's pipeline, ensuring high-quality, efficient production from pre-clinical stages through clinical trials. "We are honored and thrilled to join forces with AAHI, a pioneer in immune-enhancing technologies and sustainable vaccine solutions," said Soung Joon Kim, CEO of Quratis. "This partnership aligns perfectly with our vision of making people happy and healthy through borderless healthcare innovations. By supporting AAHI's pipeline, we expect to create value not only for global health, but also for our shareholders through long-term growth opportunities.' The partnership builds on existing collaborations, including the co-development of the ID93+GLA-SE tuberculosis vaccine candidate (QTP101), and underscores a shared commitment to strengthening international vaccine supply chains, advancing equitable access, and fostering worldwide manufacturing capacity for sustainable program deployment. For more information about this partnership or to explore collaboration opportunities, and order pre clinical materials please contact info@ About Access to Advanced Health Institute (AAHI) Access to Advanced Health Institute (AAHI) is a global leader in developing practical, cost-effective vaccines to combat deadly diseases such as tuberculosis, malaria, and HIV. With a mission to translate high-impact science into scalable, field-ready solutions, AAHI breaks through barriers in global health by creating innovative vaccine formulations, building worldwide manufacturing capacity, and fostering partnerships to ensure sustainable, equitable health outcomes. For more information, visit or contact us at info@ About Quratis Quratis Inc. is a leading biopharmaceutical company specializing in innovative vaccine development and advanced biologics manufacturing. With a state-of-the-art GMP facility and strong global partnerships, Quratis is at the forefront of developing next-generation vaccines against infectious diseases, including tuberculosis, COVID-19, schistosomiasis, and neglected tropical diseases. In addition to its core vaccine pipeline, Quratis offers superior CDMO capabilities, including expertise in mRNA–LNP drug delivery platforms that provide seamless bench-to-field support from research through commercial production. By combining cutting-edge R&D with scalable manufacturing, Quratis is committed to delivering high-quality, accessible, and life-saving solutions to patients worldwide. For more information, visit
Business Wire
an hour ago
- Business Wire
KBRA Assigns AA- Rating to Various Pennsylvania Turnpike Commission Turnpike Revenue Bonds; Affirms Related Ratings
NEW YORK--(BUSINESS WIRE)--KBRA assigns a long-term rating of AA- to the Pennsylvania Turnpike Commission: Turnpike Revenue Bonds, Series B-1 of 2025; Turnpike Revenue Bonds, Series B-2 of 2025; Turnpike Revenue Refunding Bonds, Third Series of 2025, Sub-series A; and, Turnpike Revenue Refunding Bonds, Third Series of 2025, Sub-series B. KBRA additionally affirms the long-term ratings of AA- for the Commission's outstanding Turnpike Revenue Bonds, A+ for the Commission's outstanding Turnpike Subordinate Revenue Bonds, and AA- for the Commission's outstanding Motor License Fund-Enhanced Turnpike Subordinate Special Revenue Bonds. The Outlook for each obligation is Stable. Key Credit Considerations The rating actions reflect the following key credit considerations: Credit Positives The Turnpike System is a highly essential, statewide, regional toll road system with limited competition. The Commission has full rate setting autonomy which, together with prudent finance management and controls, has supported strong margins and stable debt service coverage. Credit Challenges The Commission's O&M, capital and existing debt obligations, including its outstanding Act 44/89 obligations, are substantial and require annual toll increases, the cumulative effect of which may at some point dampen traffic demand, reducing operating margins and financial flexibility. The planned issuance of $3.6 billion in senior obligations per the 10-year capital plan may pressure subordinate obligation coverage if actual traffic demand is materially weaker than forecast, although the Commission's capital plans remain flexible if traffic volumes are not consistent with forecasts. Rating Sensitivities For Upgrade A sustained trend of increasing net revenue resulting in debt service coverages well in excess of the Commission's targets of 2.0x annual debt service on senior lien, 1.30x combined annual senior and subordinate debt service and 1.20x annual debt service for all obligations. For Downgrade A sustained decline in net revenue DSCRs below the Commission's targets for all obligations. To access ratings and relevant documents, click here. Methodologies Public Finance: U.S. Public Toll Roads, Bridges & Tunnels Revenue Bond Rating Methodology Public Finance: U.S. Special Tax Revenue Bond Rating Methodology ESG Global Rating Methodology Disclosures A description of all substantially material sources that were used to prepare the credit rating and information on the methodology(ies) (inclusive of any material models and sensitivity analyses of the relevant key rating assumptions, as applicable) used in determining the credit rating is available in the Information Disclosure Form(s) located here. Information on the meaning of each rating category can be located here. Only those ratings on securities issued by this Issuer that also are denoted on the Security Ratings tab for this Issuer on as 'endorsed' by Kroll Bond Rating Agency Europe Limited into the European Union and/or by Kroll Bond Rating Agency UK Limited into the UK are covered by the disclosures set forth in this press release and the corresponding Information Disclosure Form. No other ratings on issuances by this Issuer have been endorsed into the European Union or the UK, and the disclosures set forth herein and in the corresponding Information Disclosure Form are inapplicable to those ratings and may not be used for regulatory purposes by European Union or UK investors in these securities. Further disclosures relating to this rating action are available in the Information Disclosure Form(s) referenced above. Additional information regarding KBRA policies, methodologies, rating scales and disclosures are available at About KBRA Kroll Bond Rating Agency, LLC (KBRA), one of the major credit rating agencies (CRA), is a full-service CRA registered with the U.S. Securities and Exchange Commission as an NRSRO. Kroll Bond Rating Agency Europe Limited is registered as a CRA with the European Securities and Markets Authority. Kroll Bond Rating Agency UK Limited is registered as a CRA with the UK Financial Conduct Authority. In addition, KBRA is designated as a Designated Rating Organization (DRO) by the Ontario Securities Commission for issuers of asset-backed securities to file a short form prospectus or shelf prospectus. KBRA is also recognized as a Qualified Rating Agency by Taiwan's Financial Supervisory Commission and is recognized by the National Association of Insurance Commissioners as a Credit Rating Provider (CRP) in the U.S. Doc ID: 1010958
